MedTrace Logo

A Phase 1/2 Study of SC-43 in Combination With Cisplatin

NCT04733521 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-02-02

No results posted yet for this study

Summary

SC-43 is STAT3 inhibitor. Based on the phase I data of SC-43 monotherapy, this is a Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination with Cisplatin in Subjects with Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma

Conditions

  • Advanced Non-small-cell Lung Cancer
  • Advanced Biliary Tract Cancer

Interventions

DRUG

SC-43

SC-43 oral, every day of 21-day cycle

DRUG

Cisplatin

cisplatin 75mg/m2 on day 1 of 21-day cycle

Sponsors & Collaborators

  • RaND Biosciences

    lead INDUSTRY

Principal Investigators

  • In-Jae Oh, MD · Chonnam National University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-09-30
Completion
2023-09-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733521 on ClinicalTrials.gov